Several potential mechanisms of acquired venetoclax resistance in AML and other leukemias are discussed, including modulation of expression levels of the BCL2 target and compensatory upregulation of BCL2 paralogs and acquired mutations in BCL2 that affect drug binding. The gene discussed is BCL2; the disease is leukemia.